ReviewNPJ vaccines2020
Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens.
Review in NPJ vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Access to licenced vaccines for high-threat infectious diseases: a scoping review and interpretive analysis of Ebola virus disease.BMC infectious diseases · 2026Article
- Cancer Vaccines: Mechanisms, Clinical Applications, Challenges, and Future Directions in Precision Medicine.Current cancer drug targets · 2026Review
- Expanding modeling boundaries to design more resilient vaccine supply networks.Health care management science · 2025Article
- Modeling Supply and Demand Dynamics of Vaccines against Epidemic-Prone Pathogens: Case Study of Ebola Virus Disease.Vaccines · 2023Article
- Evolution of the viral genomes of SARS-CoV-2 in association with the changes in local condition: a genomic epidemiological study of a suburban city of Japan.DNA research : an international journal for rapid publication of reports on genes and genomes · 2023Article
- Death Reporting in Breakthrough and Unvaccinated SARS-CoV-2 Infection Cases.Disaster medicine and public health preparedness · 2023Article
- In Silico Studies to Support Vaccine Development.Pharmaceutics · 2023Review
- Article
- Predicting the combined effects of case isolation, safe funeral practices, and contact tracing during Ebola virus disease outbreaks.PloS one · 2023Article
- Leveraging WHO's Global Benchmarking Tool to strengthen capacity in clinical trials oversight for public health emergencies: the GHPP VaccTrain model.Globalization and health · 2022Article
- COVID-19 Vaccines.Infectious disease clinics of North America · 2022Review
- "A matter of time": Evidence-making temporalities of vaccine development in the COVID-19 media landscape.Time & society · 2022Article
- Medical countermeasures against henipaviruses: a review and public health perspective.The Lancet. Infectious diseases · 2022Review
- Dynamic Regulatory Assessment: evolving the European Regulatory Framework for the Benefit of Patients and Public Health-an EFPIA View.Clinical therapeutics · 2022Article
- Article
- Fractal-fractional order mathematical vaccine model of COVID-19 under non-singular kernel.Chaos, solitons, and fractals · 2021Article
- 'Learn from the lessons and don't forget them': identifying transferable lessons for COVID-19 from meningitis A, yellow fever and Ebola virus disease vaccination campaigns.BMJ global health · 2021Review
- Next Steps for Efficacy Evaluation in Clinical Trials of COVID-19 Vaccines.Engineering (Beijing, China) · 2021Article
- Perspectives in the study of the political economy of COVID-19 vaccine regulation.Regulation & governance · 2021Article
- Recommendations for acceleration of vaccine development and emergency use filings for COVID-19 leveraging lessons from the novel oral polio vaccine.NPJ vaccines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The world is experiencing an unprecedented global pandemic of coronavirus disease 2019 (COVID-19) caused by a novel coronavirus, Severe Acute Respiratory Syndrome-coronavirus-2 (SARS-CoV-2). Development of new vaccines and therapeutics are important to achieve long-term prevention and control of the virus. Experience gained in the development of vaccines for Ebola virus disease provide important lessons in the regulatory, clinical, and manufacturing process that can be applied to SARS-CoV-2 and other epidemic pathogens. This report outlines the main lessons learned by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD) during development of an Ebola Zaire vaccine (ERVEBO®) and looks ahead to critical lessons beyond vaccine development. It highlights focus areas for public-private partnership and regulatory harmonization that can be directly applied to current vaccine development efforts for SARS-CoV-2, while drawing attention to the need for parallel consideration of issues beyond development that are equally important to achieve global preparedness and response goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.